Biological fluid biomarkers in neurodegenerative parkinsonism (original) (raw)

• de Rijk, M. C. et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol. Neurosurg. Psychiatry 62, 10–15 (1997).
  CAS PubMed PubMed Central Google Scholar
• Miller, D. C., Hafez, K. S., Stewart, A., Montie, J. E. & Wei, J. T. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 98, 1169–1178 (2003).
  PubMed Google Scholar
• O'Sullivan, S. S. et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131, 1362–1372 (2008).
  CAS PubMed Google Scholar
• Hughes, A. J., Daniel, S. E., Ben-Shlomo, Y. & Lees, A. J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861–870 (2002).
  PubMed Google Scholar
• Litvan, I. et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 48, 119–125 (1997).
  CAS PubMed Google Scholar
• Osaki, Y. et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov. Disord. 19, 181–189 (2004).
  PubMed Google Scholar
• Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181–184 (1992).
  CAS PubMed PubMed Central Google Scholar
• Osaki, Y. et al. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology 59, 1486–1491 (2002).
  CAS PubMed Google Scholar
• Rajput, A. H., Rozdilsky, B. & Rajput, A. Accuracy of clinical diagnosis in parkinsonism—a prospective study. Can. J. Neurol. Sci. 18, 275–278 (1991).
  CAS PubMed Google Scholar
• Schrag, A., Ben-Shlomo, Y. & Quinn, N. How valid is the clinical diagnosis of Parkinson's disease in the community? J. Neurol. Neurosurg. Psychiatry 73, 529–534 (2002).
  CAS PubMed PubMed Central Google Scholar
• Katzenschlager, R., Cardozo, A., Avila Cobo, M. R., Tolosa, E. & Lees, A. J. Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. Mov. Disord. 18, 1123–1131 (2003).
  PubMed Google Scholar
• Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997).
  CAS PubMed Google Scholar
• Lewy, F. H. Paralysis agitans. In Handbuch der Neurologie (Ed. Lawandowsky, M.) 920–958 (Springer-Verlag, Berlin, 1912).
  Google Scholar
• Kosaka, K. Diffuse Lewy body disease in Japan. J. Neurol. 237, 197–204 (1990).
  CAS PubMed Google Scholar
• McKeith, I. G. et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113–1124 (1996).
  CAS PubMed Google Scholar
• Polymeropoulos, M. H. et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274, 1197–1199 (1996).
  CAS PubMed Google Scholar
• Mollenhauer, B. et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213, 315–325 (2008).
  CAS PubMed Google Scholar
• Tokuda, T. et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162–166 (2006).
  CAS PubMed Google Scholar
• Barber, R., Panikkar, A. & McKeith, I. G. Dementia with Lewy bodies: diagnosis and management. Int. J. Geriatr. Psychiatry 16 (Suppl. 1), S12–S18 (2001).
  PubMed Google Scholar
• Holmberg, B., Johnels, B., Blennow, K. & Rosengren, L. Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov. Disord. 18, 186–190 (2003).
  PubMed Google Scholar
• Kanemaru, K., Kameda, N. & Yamanouchi, H. Decreased CSF amyloid-β42 and normal tau levels in dementia with Lewy bodies. Neurology 54, 1875–1876 (2000).
  CAS PubMed Google Scholar
• Sjögren, M. et al. CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural Transm. 107, 563–579 (2000).
  PubMed Google Scholar
• Verbeek, M. M. et al. Cerebrospinal fluid Aβ42 levels in multiple system atrophy. Mov. Disord. 19, 238–240 (2004).
  PubMed Google Scholar
• Mollenhauer, B. et al. β-amlyoid1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 22, 200–208 (2006).
  CAS PubMed Google Scholar
• Spillantini, M. G. & Goedert, M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21, 428–433 (1998).
  CAS PubMed Google Scholar
• Perl, D. P. Neuropathology of Alzheimer's disease and related disorders. Neurol. Clin. 18, 847–864 (2000).
  CAS PubMed Google Scholar
• Sonnen, J. A. et al. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol. 7, 704–714 (2008).
  CAS PubMed PubMed Central Google Scholar
• Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 6, 734–746 (2007).
  PubMed Google Scholar
• Clark, L. N. et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69, 1270–1277 (2007).
  CAS PubMed Google Scholar
• Balducci, C. et al. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov. Disord. 22, 1481–1484 (2007).
  PubMed Google Scholar
• Zhang, J. et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129, 526–529 (2008).
  CAS PubMed Google Scholar
• Litvan, I. et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome). Neurology 46, 922–930 (1996).
  CAS PubMed Google Scholar
• Steele, J. C., Richardson, J. C. & Olszewski, J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol. 10, 333–359 (1964).
  CAS PubMed Google Scholar
• Williams, D. R. et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 128, 1247–1258 (2005).
  PubMed Google Scholar
• Williams, D. R. et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 130, 1566–1576 (2007).
  PubMed Google Scholar
• Jellinger, K. A., Bancher, C., Hauw, J. J. & Verny, M. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J. Neurol. Neurosurg. Psychiatry 59, 106 (1995).
  CAS PubMed PubMed Central Google Scholar
• Noguchi, M. et al. Decreased β-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J. Neurol. Sci. 237, 61–65 (2005).
  CAS PubMed Google Scholar
• Borroni, B. et al. Pattern of tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol. Aging 30, 34–40 (2009).
  CAS PubMed Google Scholar
• Borroni, B. et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71, 1796–1803 (2008).
  CAS PubMed Google Scholar
• Gai, W. P., Power, J. H., Blumbergs, P. C. & Blessing, W. W. Multiple-system atrophy: a new α-synuclein disease? Lancet 352, 547–548 (1998).
  CAS PubMed Google Scholar
• Petzold, A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 233, 183–198 (2005).
  CAS PubMed Google Scholar
• Holmberg, B., Rosengren, L., Karlsson, J. E. & Johnels, B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov. Disord. 13, 70–77 (1998).
  CAS PubMed Google Scholar
• Brettschneider, J. et al. Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov. Disord. 21, 2224–2227 (2006).
  PubMed Google Scholar
• Sanchez-Juan, P. et al. CSF tests in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology 67, 637–643 (2006).
  CAS PubMed Google Scholar
• Otto, M. et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. Neurosci. Lett. 225, 210–212 (1997).
  CAS PubMed Google Scholar
• Rebeiz, J. J., Kolodny, E. H. & Richardson, E. P., Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch. Neurol. 18, 20–33 (1968).
  CAS PubMed Google Scholar
• Boeve, B. F. et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53, 795–800 (1999).
  CAS PubMed Google Scholar
• Hodges, J. R. et al. Clinicopathological correlates in frontotemporal dementia. Ann. Neurol. 56, 399–406 (2004).
  PubMed Google Scholar
• Urakami, K. et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J. Neurol. Sci. 183, 95–98 (2001).
  CAS PubMed Google Scholar
• Bian, H. et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70, 1827–1835 (2008).
  CAS PubMed Google Scholar
• Riemenschneider, M. et al. Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration. Neurology 58, 1622–1628 (2002).
  CAS PubMed Google Scholar
• Pijnenburg, Y. A. et al. CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging. J. Neurol. Neurosurg. Psychiatry 77, 246–248 (2006).
  CAS PubMed PubMed Central Google Scholar
• Schoonenboom, N. S. et al. Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62, 1580–1584 (2004).
  CAS PubMed Google Scholar
• Fabre, S. F. et al. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E ε4 frequency, but no tau gene mutations. Exp. Neurol. 168, 413–418 (2001).
  CAS PubMed Google Scholar
• Green, A. J., Harvey, R. J., Thompson, E. J. & Rossor, M. N. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci. Lett. 259, 133–135 (1999).
  CAS PubMed Google Scholar
• Mehta, P. D. et al. Plasma and cerebrospinal fluid levels of amyloid β proteins 1–40 and 1–42 in Alzheimer disease. Arch. Neurol. 57, 100–105 (2000).
  CAS PubMed Google Scholar
• Pijnenburg, Y. A. et al. Decreased cerebrospinal fluid amyloid β(1–40) levels in frontotemporal lobar degeneration. J. Neurol. Neurosurg. Psychiatry 78, 735–737 (2007).
  CAS PubMed PubMed Central Google Scholar
• de Jong, D. et al. CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 78, 936–938 (2007).
  CAS PubMed PubMed Central Google Scholar
• Zijlmans, J. C., Daniel, S. E., Hughes, A. J., Revesz, T. & Lees, A. J. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov. Disord. 19, 630–640 (2004).
  PubMed Google Scholar
• Andreasen, N. et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 53, 1488–1494 (1999).
  CAS PubMed Google Scholar
• Vigo-Pelfrey, C. et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 45, 788–793 (1995).
  CAS PubMed Google Scholar
• de Jong, D., Jansen, R. W., Kremer, B. P. & Verbeek, M. M. Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J. Gerontol. A. Biol. Sci. Med. Sci. 61, 755–758 (2006).
  PubMed Google Scholar
• Kosunen, O. et al. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol. 91, 185–193 (1996).
  CAS PubMed Google Scholar
• Hakim, S. & Adams, R. D. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J. Neurol. Sci. 2, 307–327 (1965).
  CAS PubMed Google Scholar
• Schott, J. M. et al. Shunt responsive progressive supranuclear palsy? Mov. Disord. 22, 902–903 (2007).
  PubMed Google Scholar
• Savolainen, S., Paljarvi, L. & Vapalahti, M. Prevalence of Alzheimer's disease in patients investigated for presumed normal pressure hydrocephalus: a clinical and neuropathological study. Acta Neurochir. (Wien) 141, 849–853 (1999).
  CAS Google Scholar
• Kudo, T. et al. Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry Clin. Neurosci. 54, 199–202 (2000).
  CAS PubMed Google Scholar
• Kapaki, E. N. et al. Cerebrospinal fluid tau, phospho-tau181 and β-amyloid1–42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur. J. Neurol. 14, 168–173 (2007).
  CAS PubMed Google Scholar
• Bateman, R. J., Wen, G., Morris, J. C. & Holtzman, D. M. Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker. Neurology 68, 666–669 (2007).
  CAS PubMed Google Scholar
• Lewczuk, P. et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 409, 1–4 (2006).
  CAS PubMed Google Scholar
• Blennow, K. et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci. Lett. 419, 18–22 (2007).
  CAS PubMed Google Scholar
• Kaiser, E., Schonknecht, P., Thomann, P. A., Hunt, A. & Schroder, J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and β-amyloid (1–42). Neurosci. Lett. 417, 193–195 (2007).
  CAS PubMed Google Scholar
• Lewczuk, P. et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides. Clin. Chem. 52, 332–334 (2006).
  CAS PubMed Google Scholar
• Weisskopf, M. G., O'Reilly, E., Chen, H., Schwarzschild, M. A. & Ascherio, A. Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166, 561–567 (2007).
  CAS PubMed Google Scholar
• Davis, J. W. et al. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am. J. Epidemiol. 144, 480–484 (1996).
  CAS PubMed Google Scholar
• de Lau, L. M., Koudstaal, P. J., Hofman, A. & Breteler, M. M. Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 58, 797–800 (2005).
  CAS PubMed Google Scholar
• Alonso, A., Rodriguez, L. A., Logroscino, G. & Hernan, M. A. Gout and risk of Parkinson disease: a prospective study. Neurology 69, 1696–1700 (2007).
  PubMed Google Scholar
• Duan, W. et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 80, 101–110 (2002).
  CAS PubMed Google Scholar
• Church, W. H. & Ward, V. L. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res. Bull. 33, 419–425 (1994).
  CAS PubMed Google Scholar
• Schwarzschild, M. A. et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 65, 716–723 (2008).
  PubMed PubMed Central Google Scholar
• Bogdanov, M. et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131, 389–396 (2008).
  PubMed Google Scholar
• Connolly, J., Siderowf, A., Clark, C. M., Mu, D. & Pratico, D. F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients. Cogn. Behav. Neurol. 21, 83–86 (2008).
  PubMed Google Scholar
• Sato, S., Mizuno, Y. & Hattori, N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64, 1081–1083 (2005).
  CAS PubMed Google Scholar
• Barbour, R. et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 5, 55–59 (2008).
  CAS PubMed Google Scholar
• Michell, A. W., Luheshi, L. M. & Barker, R. A. Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci. Lett. 381, 294–298 (2005).
  CAS PubMed Google Scholar
• Tamo, W. et al. Expression of α-synuclein, the precursor of non-amyloid β component of Alzheimer's disease amyloid, in human cerebral blood vessels. Neurosci. Lett. 326, 5–8 (2002).
  CAS PubMed Google Scholar
• Hoepken, H. H. et al. Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp. Neurol. 212, 307–313 (2008).
  CAS PubMed Google Scholar
• Michell, A. W., Lewis, S. J., Foltynie, T. & Barker, R. A. Biomarkers and Parkinson's disease. Brain 127, 1693–1705 (2004).
  CAS PubMed Google Scholar
• Tolosa, E., Wenning, G. & Poewe, W. The diagnosis of Parkinson's disease. Lancet Neurol. 5, 75–86 (2006).
  PubMed Google Scholar
• Gibb, W. R. & Lees, A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51, 745–752 (1988).
  CAS PubMed PubMed Central Google Scholar
• Williams, D. R. & Lees, A. J. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 8, 270–279 (2009).
  PubMed Google Scholar
• Litvan, I. et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47, 1–9 (1996).
  CAS PubMed Google Scholar
• Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670–676 (2008).
  CAS PubMed PubMed Central Google Scholar